Literature DB >> 8129773

Nomenclature of systemic vasculitides. Proposal of an international consensus conference.

J C Jennette1, R J Falk, K Andrassy, P A Bacon, J Churg, W L Gross, E C Hagen, G S Hoffman, G G Hunder, C G Kallenberg.   

Abstract

The following are some of the conclusions and proposals made at the Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitis. 1. Although not a prerequisite component of the definitions, patient age is recognized as a useful discriminator between Takayasu arteritis and giant cell (temporal) arteritis. 2. The name "polyarteritis nodosa," or alternatively, the name "classic polyarteritis nodosa," is restricted to disease in which there is arteritis in medium-sized and small arteries without involvement of smaller vessels. Therefore, patients with vasculitis affecting arterioles, venules, or capillaries, including glomerular capillaries (i.e., with glomerulonephritis), are excluded from this diagnostic category. 3. The name "Wegener's granulomatosis" is restricted to patients with granulomatous inflammation. Patients with exclusively nongranulomatous small vessel vasculitis involving the upper or lower respiratory tract (e.g., alveolar capillaritis) fall into the category of microscopic polyangiitis (microscopic polyarteritis). 4. The term "hypersensitivity vasculitis" is not used. Most patients who would have been given this diagnosis fall into the category of microscopic polyangiitis (microscopic polyarteritis) or cutaneous leukocytoclastic angiitis. 5. The name "microscopic polyangiitis," or alternatively, "microscopic polyarteritis," connotes pauci-immune (i.e., few or no immune deposits) necrotizing vasculitis affecting small vessels, with or without involvement of medium-sized arteries. Cryoglobulinemic vasculitis, Henoch-Schönlein purpura, and other forms of immune complex-mediated small vessel vasculitis must be ruled out to make this diagnosis. 6. The name "cutaneous leukocytoclastic angiitis" is restricted to vasculitis in the skin without involvement of vessels in any other organ. 7. Mucocutaneous lymph node syndrome must be present to make a diagnosis of Kawasaki disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8129773     DOI: 10.1002/art.1780370206

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  726 in total

1.  Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.

Authors:  M Gencik; S Borgmann; R Zahn; E Albert; T Sitter; J T Epplen; H Fricke
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

Review 2.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 3.  Clinical trials review: vasculitis.

Authors:  D K Ledford
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

4.  Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns.

Authors:  R C Wong; R A Silvestrini; J A Savige; D A Fulcher; E M Benson
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

5.  Systemic vasculitis: epidemiology, classification and environmental factors.

Authors:  D G Scott; R A Watts
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

Review 6.  Pathogenesis and treatment of ANCA-associated systemic vasculitis.

Authors:  A D Salama
Journal:  J R Soc Med       Date:  1999-09       Impact factor: 5.344

7.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

Review 8.  Polyarteritis nodosa and microscopic polyangiitis: etiologic and diagnostic considerations.

Authors:  Laura B Hughes; S Louis Bridges
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

Review 9.  Combination therapy in autoimmune disease: vasculitis.

Authors:  D Carruthers; P Bacon
Journal:  Springer Semin Immunopathol       Date:  2001

10.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.